DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» SillaJen
SillaJen
Immunotherapy and Chimeric Antigen Receptor T-Cell Therapy in Hepatocellular Carcinoma
Sillajen to Discontinue PHOCUS Trial for Advanced Liver Cancer
Sorafenib in Patients with Hepatocellular Carcinoma—Results of the Observational INSIGHT Study Tom M
Download
WO 2018/195552 Al 25 October 2018 (25.10.2018) W !P O PCT
Lee's Pharmaceutical Holdings Limited
Sillajen and Lee's Pharmaceutical Announce First Patient Enrolled In
Transgene Provides an Update After the Interim Futility Analysis of the PHOCUS Study of Pexa-Vec in Liver Cancer
Oncolytic Viruses Get a Boost with First FDA-Approval Recommendation
Targovax ASA Lilleakerveien 2 C TARGOVAX ASA 0283 Oslo Norway (A Public Limited Company Incorporated Under the Laws of Norway)
Beijing Shenogen Pharma Group Limited and Lee's Pharmaceutical
Progress in Clinical Oncolytic Virus-Based Therapy for Hepatocellular Carcinoma
Perspectives on Immunotherapy Utilization for Hepatobiliary Cancers in the United States
Pexastimogene Devacirepvec (Pexa-Vec) for Hepatocellular Carcinoma – First Line NIHRIO (HSRIC) ID: 4760 NICE ID: 9538
Safety, Biodistribution and Viral Shedding of Oncolytic Vaccinia Virus
Transgene and Sillajen Announce Revised Agreement for Pexa-Vec Oncolytic Viral Therapy and Provide Update on Clinical Development
Edison Research Template
Regeneron and Sillajen Announce Immuno-Oncology Clinical Study Agreement for Combination Treatment in Kidney Cancer
Top View
Amplification of Oncolytic Vaccinia Virus Widespread Tumor Cell Killing By
Centerwatch Weekly, August 19, 2019
VT Multi-Asset Absolute Return Fund Semi-Annual Report
Recent Progresses of Oncolytic Immunotherapy Jean-François Fonteneau
BIO Digital Sample Attendee List As of June 5, 2020
Transgene Announces First Patient Randomized in Multinational Phase 3 Trial for Pexa-Vec Oncolytic Immunotherapy in Advanced Liver Cancer
Transgene R&D Update
EPA Staff Assessment Report on Application APP202601
20170424 Pr Phocus Fpi Eu
Immunotherapy for Hepatocellular Carcinoma: a 2021 Update
Transgene Pipeline Readouts in H218
Adverum Biotechnologies Announces Leadership Transition
Transgene and Léon Bérard Cancer Center
Sillajen and Lee's Pharmaceutical Announce Approval by the China
A Phase 2B Randomized Single-Blinded Trial of JX